Lantern Pharma receives clearance from FDA to advance LP-184 into clinical studies for solid tumors and CNS cancers
June 13, 2023
Lantern Pharma Inc. has received IND clearance from the FDA for LP-184, which is being developed for advanced solid tumors and central nervous system (CNS) cancers.
